Loading...
•
Mar 31
TG Therapeutics Q1 2025 Earnings Report
TG Therapeutics posted a profitable Q1 2025, driven by strong BRIUMVI sales and raised full-year revenue guidance.
Key Takeaways
TG Therapeutics delivered a profitable first quarter of 2025, achieving $120.9 million in revenue primarily from BRIUMVI sales and reporting a net income of $5.1 million. The company raised full-year revenue targets on the back of strong adoption and promising long-term data.
Recorded net income of $5.1 million, turning profitable from a loss last year
Generated $119.7 million in U.S. BRIUMVI product revenue
Raised full-year U.S. BRIUMVI revenue guidance to $560 million
Reported strong efficacy and safety from 5-year BRIUMVI data
TG Therapeutics
TG Therapeutics
TG Therapeutics Revenue by Segment
TG Therapeutics Revenue by Geographic Location
Revenue by Segment
BRIUMVI Revenue
CapyFin.comLic./Milestone/Other Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
TG Therapeutics raised its full-year 2025 revenue outlook on increased BRIUMVI sales momentum and broader commercial expansion.
Positive Outlook
- Raised BRIUMVI U.S. revenue guidance to $560M for FY2025
- Raised global revenue guidance to $575M for FY2025
- Q2 2025 BRIUMVI revenue expected at $135M
- Anticipates full-year operating expenses of ~$300M (excluding certain items)
- Continued positive reception and adoption of BRIUMVI therapy
Challenges Ahead
- License and milestone revenue declined year-over-year
- Higher SG&A costs due to commercialization efforts
- Increased R&D spending driven by subcutaneous BRIUMVI development
- Dependence on a single product for majority of revenue
- Regulatory and market risks remain for ongoing pipeline development